Xpovio Conditionally Approved in China for Heavily Treated Patients

Xpovio Conditionally Approved in China for Heavily Treated Patients

314652

Xpovio Conditionally Approved in China for Heavily Treated Patients

China’s National Medical Products Administration (NMPA) has conditionally approved a combination of Xpovio (selinexor) and the corticosteroid dexamethasone to treat adults with relapsed or refractory multiple myeloma (RRMM) who received at least three prior therapies. This includes patients whose disease failed to respond to at least one immunomodulatory agent (IMiD), one proteasome inhibitor (PI), and one CD38 inhibitor and who showed disease progression on their last therapy. “I am pleased that XPOVIO is Antengene’s first product…

You must be logged in to read/download the full post.